The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.